市場調査レポート

世界のヒアルロン酸粘弾性補助に関する医師への調査:2011年

International Hyaluronic Acid Viscosupplementation Physician Survey 2011

発行 iData Research Inc. 商品コード 203688
出版日 ページ情報 英文 91 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界のヒアルロン酸粘弾性補助に関する医師への調査:2011年 International Hyaluronic Acid Viscosupplementation Physician Survey 2011
出版日: 2011年07月01日 ページ情報: 英文 91 Pages

当商品の販売は、2016年06月17日を持ちまして終了しました。

概要

当レポートでは、ヒアルロン酸粘弾性補助の使用に関して100名以上の整形外科医に調査を実施し、使用形態と製品、実施件数、好みのブランドなどについてまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

  • 概要
  • 回答者の地域
  • 競合ブランド
  • 購買チャネル
  • 価格の重要性
  • 単回注射への満足度
  • 購買決定
  • ヒアルロン酸治療後の疼痛緩和までの時間

第2章 調査のハイライト

  • 回答者の特性
    • 医師プロファイル
    • 購入チャネル
  • 回答サマリー
    • 製品に対する姿勢
    • 製品インセンティブ
    • 患者プロファイル
    • 好みのブランド

第3章 調査方法

  • 調査概要
  • 調査サービス
  • 調査方法

第4章 ヒアルロン酸粘弾性補助に関する調査結果

  • 質問1:実施年数
    • 地域別
    • 国別
  • 質問2:月間患者数
  • 質問3:ブランド
  • 質問4:ブランド選択理由
  • 質問5:単回注射の使用増加傾向
  • 質問6:単回注射製品への満足度
  • 質問7:その後人工膝関節全置換術に移行する患者の割合
  • 質問8:ヒアルロン酸および保存療法後の人工膝関節全置換術までの時間
  • 質問9:人工膝関節全置換術前に用いられるヒアルロン酸注射の種類
  • 質問10:ブランド購入インセンティブ
  • 質問11:受領したインセンティブ
  • 質問12:異なるブランドに変更した理由
  • 質問13:ヒアルロン酸から最も利益を得た患者群
  • 質問14:価格の重要性
  • 質問15:購入チャネルの性質

付録

図表

目次
Product Code: iDATA_INHAS11_RPT

Over 100 orthopedic specialists were surveyed regarding their perceptions and usage of hyaluronic acid viscosupplementation during the 2011 American Academy of Orthopaedic Surgeons (AAOS) conference. This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid viscosupplement product, including single injection, 3-injection and 5-injection therapy regimes. Satisfaction with current offerings is examined in detail, along with the market penetration of single injection products. The data presented describes practice experience, practice volume and the attitudes of the respondents to the product, as well as how these factors interact. In addition to physician brand preference, this survey report describes the proportion of doctors who would be willing to switch to a single injection product like Genzyme' s Synvisc-One®. The results of the survey indicated a high degree of familiarity with the product within the physician community. There is a general divide in the U.S. medical community between HA brands that are used for a majority of procedures within a practice. The respondents were asked to rate their satisfaction with the various injection products. This in term was compared to the probability of switching brands, and the possible motivating reasons for doing so.

Table of Contents

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1. OVERVIEW
  • 1.2. RESPONDENT PRACTICE LOCATION
  • 1.3. COMPETING BRANDS
  • 1.4. PURCHASING CHANNELS
  • 1.5. IMPORTANCE OF PRICING
  • 1.6. SATISFACTION WITH SINGLE INJECTION
  • 1.7. PURCHASING DECISIONS
  • 1.8. TIME TO PAIN RELIEF AFTER HA TREATMENT

SURVEY HIGHLIGHTS

  • 2.1. RESPONDENT CHARACTERISTICS
    • 2.1.1. Doctor Profile
    • 2.1.2. Purchasing Channel
  • 2.2. RESPONSE SUMMARY
    • 2.2.1. Attitudes Towards Products
    • 2.2.2. Product Incentives
    • 2.2.3. Patient Profile
    • 2.2.4. Brand Preferences

RESEARCH METHODOLOGY

  • 3.1. RESEARCH OVERVIEW
  • 3.2. RESEARCH SERVICES
  • 3.3. SURVEY METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Sample Population Preparation
    • Step 3: Preparation, Questionnaire Design & Administration
    • Step 4: Reporting and Analysis
    • Step 5: Customer Feedback

HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS

  • 4.1. QUESTION 1: YEARS OF PRACTICE
    • 4.1.1. Practice Experience by Global Region
    • 4.1.2. Country of Origin
  • 4.2. QUESTION 2: HYALURONIC ACID (HA) VISCOSUPPLEMENT PATIENTS PER MONTH
    • 4.2.1. HA Patients per Month
    • 4.2.2. Monthly HA Patients by Practice Experience
  • 4.3. QUESTION 3: HA UTILIZATION BY BRAND
  • 4.4. QUESTION 4:REASONS FOR CHOOSING HA BRAND
    • 4.4.1. Reasons for Choosing Brand
    • 4.4.2. Reasons for Choosing Brand by Brand Preference
  • 4.5. QUESTION 5: LIKELIHOOD OF INCREASING SINGLE INJECTION USE
  • 4.6. QUESTION 6: SATISFACTION WITH SINGLE INJECTION PRODUCTS
    • 4.6.1. Satisfaction with Single Injection
    • 4.6.2. Likelihood of Increasing Single Injection Use by Satisfaction
  • 4.7. QUESTION 7: PERCENTAGE OF HA PATIENTS THAT SUBSEQUENTLY GO ON TO TOTAL KNEE ARTHROPLASTY (TKA)
  • 4.8. QUESTION 8: TIME TO TKA AFTER HA AND CONSERVATIVE TREATMENTS
    • 4.8.1. Time to TKA
    • 4.8.2. Time to TKA by Surgical Volume
  • 4.9. QUESTION 9: HA INJECTION TYPES USED BEFORE TKA
  • 4.10. QUESTION 10: PERCEIVED BRAND PURCHASING INCENTIVES
  • 4.11. QUESTION 11: NATURE OF INCENTIVES RECEIVED
  • 4.12. QUESTION 12: REASONS TO SWITCH TO DIFFERENT HA BRAND
    • 4.12.1. General Reasons to Switch Brands
    • 4.12.2. Reasons to Switch Brands by Brand Attribute Preference
  • 4.13. QUESTION 13: PATIENT GROUPS RECEIVING THE MOST BENEFIT FROM HA
  • 4.14. QUESTION 14: IMPORTANCE OF PRICING
  • 4.15. QUESTION 15: NATURE OF PURCHASING CHANNELS
    • 4.15.1. Purchasing Channels
    • 4.15.2. Importance of Pricing by Purchasing Channel
  • 4.16. QUESTION 16: RESPONDENT CLINICAL SETTING
  • 4.17. QUESTION 17 TO 18: TIME TO RELIEF AFTER TREATMENT
    • 4.17.1. Question 17: Time to Relief After Single Injection Treatment
    • 4.17.2. Question 18: Time to Relief After 3-Injection Treatment
    • 4.17.3. Question 19: Time to Relief After 5-Injection Treatment

APPENDIX 1: SURVEY QUESTIONS

LIST OF FIGURES

EXECUTIVE SUMMARY

SURVEY HIGHLIGHTS

RESEARCH METHODOLOGY

HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS

  • Figure 4-1: Years of Practice, 2011
  • Figure 4-2: Country of Origin, Asia, 2011
  • Figure 4-3: Country of Origin, Europe, 2011
  • Figure 4-4: Country of Origin, Latin America, 2011
  • Figure 4-5: Country of Origin, Africa, Middle East and Caribbean, 2011
  • Figure 4-6: HA Patients Treated per Month, 2011
  • Figure 4-7: Monthly HA Patients Seen by Years of Practice, 2011
  • Figure 4-8: Weighted Average for HA Brand Frequency of Use, Asia, 2011
  • Figure 4-9: Weighted Average for HA Brand Frequency of Use, Europe, 2011
  • Figure 4-10: Weighted Average for HA Brand Frequency of Use, Latin America, 2011
  • Figure 4-11: Weighted Average for HA Brand Frequency of Use, Other, 2011
  • Figure 4-12: Reasons for Choosing a HA Brand, 2011
  • Figure 4-13: Reasons for Choosing Brand by Brand Choice, Asia, 2011
  • Figure 4-14: Reasons for Choosing Brand by Brand Choice, Europe, 2011
  • Figure 4-15: Reasons for Choosing Brand by Brand Choice, Latin America, 2011
  • Figure 4-16: Reasons for Choosing Brand by Brand Choice, Middle East, Africa and Caribbean
  • Figure 4-17: Likelihood of Switching to Single Injection, 2011
  • Figure 4-18: Satisfaction with Single Injection Products, 2011
  • Figure 4-19: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
  • Figure 4-20: Percentage of HA Patients that Subsequently Go on to Total Knee Arthroplasty (TKA), 2011
  • Figure 4-21: Time to TKA After HA and Conservative Treatments, Months, 2011
  • Figure 4-22: Time to TKA in Months per Percentage of Patients that Require TKA, 2011
  • Figure 4-23: HA Injection Types Used Before TKA, Weighted Average, 2011
  • Figure 4-24: HA Injection Types Used Before TKA by Response Distribution, Asia
  • Figure 4-25: HA Injection Types Used Before TKA by Response Distribution, Europe, 2011
  • Figure 4-26: HA Injection Types Used Before TKA by Response Distribution, Latin America, 2011
  • Figure 4-27: HA Injection Types Used Before TKA by Response Distribution, Other, 2011
  • Figure 4-28: Perceived Brand Purchasing Incentives, 2011
  • Figure 4-29: Nature of Incentives Received, 2011
  • Figure 4-30: Reasons to Switch to Different HA Brand, 2011
  • Figure 4-31: Nature of Incentives Received by Brand Selection Preferences, Asia, 2011
  • Figure 4-32: Nature of Incentives Received by Brand Selection Preferences, Europe, 2011
  • Figure 4-33: Nature of Incentives Received by Brand Selection Preferences, Latin America, 2011
  • Figure 4-34: Nature of Incentives Received by Brand Selection Preferences, Middle East, Africa and Caribbean, 2011
  • Figure 4-35: Patient Groups Receiving the Most Benefit from HA, 2011
  • Figure 4-36: Importance of Pricing, 2011
  • Figure 4-37: Purchasing Channels, 2011
  • Figure 4-38: Importance of Pricing by Purchasing Channel, Asia, 2011
  • Figure 4-39: Importance of Pricing by Purchasing Channel, Europe, 2011
  • Figure 4-40: Importance of Pricing by Purchasing Channel, Latin America, 2011
  • Figure 4-41: Importance of Pricing by Purchasing Channel, Middle East Africa and Caribbean, 2011
  • Figure 4-42: Respondent Clinical Setting, 2011
  • Figure 4-43: Time to Relief After Single Injection Treatment, Weeks, 2011
  • Figure 4-44: Time to Relief After 3-Injection Treatment, Weeks, 2011
  • Figure 4-45: Time to Relief After 5-Injection Treatment, Weeks, 2011

APPENDIX 1: SURVEY QUESTIONS

LIST OF CHARTS

EXECUTIVE SUMMARY

  • Chart 1-1: Hyaluronic Acid Usage Among Survey Respondents, Latin America, 2011
  • Chart 1-2: Respondent Location by Region, 2011
  • Chart 1-3: Brand Preference Among, Africa, Middle East and Caribbean, 2011
  • Chart 1-4: Purchasing Channels, Global, 2011
  • Chart 1-5: Perceived Importance of Pricing, Global, 2011
  • Chart 1-6: Likelihood of Increasing Single Injection Use as a function of Satisfaction Rating, Asia, 2011
  • Chart 1-7: Reasons for Choosing a HA Brand, Europe, 2011
  • Chart 1-8: Time to Pain Relief in Weeks, 3-Injection Therapy, 2011

SURVEY HIGHLIGHTS

RESEARCH METHODOLOGY

HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS

  • Chart 4-1: Years of Practice, 2011
  • Chart 4-2: Respondents by Global Region, 2011
  • Chart 4-3: Country of Origin, Asia, 2011
  • Chart 4-4: Country of Origin, Europe, 2011
  • Chart 4-5: Country of Origin, Latin America, 2011
  • Chart 4-6: Country of Origin, Africa, Middle East and Caribbean, 2011
  • Chart 4-7: HA Patients per Month, 2011
  • Chart 4-8: Monthly HA Patients Seen by Years of Practice, 2011
  • Chart 4-9: Weighted Average for HA Brand Frequency of Use, Asia, 2011
  • Chart 4-10: Weighted Average for HA Brand Frequency of Use, Europe, 2011
  • Chart 4-11: Weighted Average for HA Brand Frequency of Use, Latin America, 2011
  • Chart 4-12: Weighted Average for HA Brand Frequency of Use, Other, 2011
  • Chart 4-13: Reasons for Choosing a HA Brand, 2011
  • Chart 4-14: Reasons for Choosing Brand by Brand Choice, Asia, 2011
  • Chart 4-15: Reasons for Choosing Brand by Brand Choice, Europe, 2011
  • Chart 4-16: Reasons for Choosing Brand by Brand Choice, Latin America, 2011
  • Chart 4-17: Reasons for Choosing Brand by Brand Choice, Middle East, Africa and Caribbean
  • Chart 4-18: Likelihood of Switching to Single Injection, 2011
  • Chart 4-19: Satisfaction with Single Injection Products
  • Chart 4-20: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
  • Chart 4-21: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
  • Chart 4-22: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
  • Chart 4-23: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
  • Chart 4-24: Percentage of HA Patients that Subsequently Go on to Total Knee Arthroplasty (TKA), 2011
  • Chart 4-25: Time to TKA After HA and Conservative Treatments, 2011
  • Chart 4-26: Time to TKA in Months per Percentage of Patients that Require TKA, Asia, 2011
  • Chart 4-27: Time to TKA in Months per Percentage of Patients that Require TKA, Europe, 2011
  • Chart 4-28: Time to TKA in Months per Percentage of Patients that Require TKA, Latin America, 2011
  • Chart 4-29: Time to TKA in Months per Percentage of Patients that Require TKA, Africa, Middle East and Caribbean, 2011
  • Chart 4-30: HA Injection Types Used Before TKA, Weighted Average, 2011
  • Chart 4-31: Perceived Brand Purchasing Incentives, 2011
  • Chart 4-32: Nature of Incentives Received, 2011
  • Chart 4-33: Reasons to Switch to Different HA Brand, 2011
  • Chart 4-34: Patient Groups Receiving the Most Benefit from HA, 2011
  • Chart 4-35: Importance of Pricing, 2011
  • Chart 4-36: Purchasing Channels, 2011
  • Chart 4-37: Respondent Clinical Setting, 2011

APPENDIX 1: SURVEY QUESTIONS

Back to Top